title: A Rare t(9;22;16)(q34;q11;q24) Translocation in Chronic Myeloid Leukemia for Which Imatinib Mesylate Was Effective: A Case Report.
abstract: The t(9;22)(q34;q11) translocation is found in about 90% of chronic myeloid leukemia (CML) patients. About 5-10% of CML patients have complex variant translocations involving a third chromosome in addition to chromosomes 9 and 22. Herein, we describe a CML-chronic phase male with a complex translocation involving chromosome 16, t(9;22;16)(q34;q11;q24). First, he was treated with interferon-alpha and intermittent hydroxyurea, but only a partial cytogenetic response was attained. Subsequently, the patient was treated with imatinib mesylate because of an additional chromosome abnormality, trisomy 8. A major molecular response was obtained after one year's imatinib therapy, and the follow-up chromosomal analysis performed 4 years and 3 months after the initiation of imatinib therapy displayed a normal karyotype of 46,XY.
authors.affiliation: Department of Hematology, Osaka City General Hospital, 2-13-22 Miyakojimahondori, Miyakojima-Ku, Osaka 534-0021, Japan ; Department of Hematology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-Ku, Osaka 545-8585, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Manabe
authors.forename: Yumi
authors.initials: Y
authors.lastname: Yoshii
authors.forename: Satoru
authors.initials: S
authors.lastname: Mukai
authors.forename: Erina
authors.initials: E
authors.lastname: Sakamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kanashima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Inoue
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Teshima